Ryan Joseph Sullivan

This study identifies a novel CD8+ TIL subset that uses lymphotoxin and IFN pathways to kill cancer cells, linking LTB expression to clinical response in melanoma.

The paper identifies a mature dendritic cell subtype associated with improved immune response and prognosis in melanoma patients treated with anti-PD-1 checkpoint inhibitors.

This study shows that targeting CD38 improves T cell function and restores response to immunotherapy in melanoma models.

This study uses high-throughput microfluidic technology to enrich CTCs from large blood volumes, enabling detailed molecular and morphological analysis of tumor cells in metastatic cancer patients.

This study identifies immune cell types and biomarkers in irMyocarditis using single-cell RNA sequencing and TCR analysis across heart, blood, and tumor tissues.

This study identifies molecular mechanisms of resistance to immune checkpoint blockade in metastatic melanoma using proteogenomic and spatial analyses of tumor and immune microenvironment data.

The paper develops DNA- and RNA-based models combining immune and tumor features to predict outcomes of checkpoint inhibition in melanoma.